Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Clinical Reviews in Allergy & Immunology
Erschienen in: Clinical Reviews in Allergy & Immunology 2/2018

03.10.2018

Psychosocial Mediators of Change and Patient Selection Factors in Oral Immunotherapy Trials

verfasst von: Audrey Dunn Galvin, J.O’B. Hourihane

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Health-related quality of life (HRQL) is influenced by physiological, psychological, and environmental variables and can be best understood by considering the interactions of factors that cut across multiple levels. One of the most important issues relating to treatment in food allergy is to identify, describe, and define predictors that may contribute to modify HRQL outcomes. The research presented demonstrates that measures of HRQL are able to distinguish key features of known groups (e.g. relating to reaction severity, treatment, allergen type/number, expectation of outcome) and delineate impact on hitherto unknown groups (e.g. relating to personality types and coping styles). This heterogeneity may explain why HRQL or other patient-related outcomes may differ in individuals during, or following any treatment or intervention. Patient-reported outcomes are relatively poorly defined to date. Since HRQL has only been studied in relatively few oral immunotherapy trials to date, primarily looking at caregiver HRQL, it is unclear which factors, measures, or subscales are most predictive of short- and/or long-term treatment outcomes for which type of patient, and which time points for measurement are most informative. A standardised protocol that incorporates HRQL and other relevant patient-related outcome measures and agreed definitions of outcomes would allow for the comparison of efficacy of food allergy treatments between centres, trials, or countries. Further evidence-based research aimed at exploring the effects of interventions on outcomes in food allergy is needed, including the influence of patient and parent factors on protocol design. To this end, it is vital that patient-related outcomes such as improved HRQL are seen as a primary outcome and are measured at multiple intervals during the trial duration and beyond. The creative use of methods and designs (both qualitative and quantitative) to better understand the role of HRQL in immunotherapy treatment trials will enable improved modelling of the costs, risks, and benefits of any treatment. Systematic analysis and modelling of antecedent factors, mediators, and outcomes will be important to boost intervention effects and to maximise the overall benefits of treatment.
Literatur
1.
Prescott S, Allen KJ (2011) Food allergy: riding the second wave of the allergy epidemic. Pediatr Allergy Immunol 22:155–160CrossRef
2.
Burks AW, Tang M, Sicherer S, Muraro A, Eigenmann PA, Ebisawa M, Fiocchi A, Chiang W, Beyer K, Wood R, Hourihane J, Jones SM, Lack G, Sampson HA (2012) ICON: food allergy. J Allergy Clin Immunol 129:906–920CrossRef
3.
Gupta RS, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, Holl JL (2011) The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics 128:e9–e17CrossRef
4.
Liew WK, Williamson E, Tang ML (2009) Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol 123:434–442CrossRef
5.
Mullins RJ, Dear KB, Tang ML (2015) Time trends in Australian hospital anaphylaxis admissions in 1998-1999 to 2011-2012. J Allergy Clin Immunol 136:367–375CrossRef
6.
Turner PJ, Gowland MH, Sharma V, Ierodiakonou D, Harper N, Garcez T, Pumphrey R, Boyle RJ (2015) Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. J Allergy Clin Immunol 135(4):956–963CrossRefPubMedCentral
7.
Branum AM, Lukacs SL (2009) Food allergy among children in the United States. Pediatrics 124:1549–1555CrossRef
8.
Sicherer SH, Forman JA, Noone SA (2000) Use assessment of self-administered epinephrine among food-allergic children and pediatricians. Pediatrics 105:359–362CrossRef
9.
de Silva IL, Mehr SS, Tey D, Tang ML (2008) Paediatric anaphylaxis: a 5 year retrospective review. Allergy 63:1071–1076CrossRef
10.
Umasunthar T, Leonardi-Bee J, Hodes M, Turner PJ, Gore C, Habibi P, Warner JO, Boyle RJ (2013) Incidence of fatal food anaphylaxis in people with food allergy: a systematic review and meta-analysis. Clin Exp Allergy 43:1333–1341CrossRefPubMedCentral
11.
Wassenberg J, Cochard MM, Dunngalvin A, Ballabeni P, Flokstra-de Blok BM, Newman CJ et al (2012) Parent perceived quality of life is age-dependent in children with food allergy. Pediatr Allergy Immunol 23:412–419CrossRef
12.
Grabenhenrich L, Hompes S, Gough H, Ruëff F, Scherer K, Pföhler C, Treudler R, Mahler V, Hawranek T, Nemat K, Koehli A, Keil T, Worm M (2012) Implementation of anaphylaxis management guidelines: a register-based study. PLoS One 7:e35778CrossRefPubMedCentral
13.
Dunn Galvin A, Hourihane JOB (2016) Health-related quality of life in food allergy: Impact, correlates, and predictors. Bundesgesundheitsbl © Springer-Verlag, Berlin Heidelberg
14.
Varni J, Burwinkle T, Lane M (2005) Health-related quality of life measurement in pediatric clinical practice: an appraisal and precept for future research and application. Health Qual Life Outcomes 3:34CrossRefPubMedCentral
15.
Cummings AJ, Knibb RC, King RM, Lucas JS (2010) The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review. Allergy 65(8):933–945CrossRef
16.
King RM, Knibb RC, Hourihane JO (2009) Impact of peanut allergy on quality of life, stress and anxiety in the family. Allergy 64:461–468CrossRef
17.
Lyons AC, Forde EM (2004) Food allergy in young adults: perceptions and psychological effects. J Health Psychol 9:497–504CrossRef
18.
Sicherer SH, Noone SA, Munoz-Furlong A (2001) The impact of childhood food allergy on quality of life. Ann Allergy Asthma Immunol 87:461–464CrossRef
19.
Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, Rothman M, PRO Harmonization Group (2003) Incorporating the patient’s perspective into drug development and communication: an ad hoc task force report on the patient-reported outcomes (PRO) harmonization group meeting at the Food and Drug Administration, February 16, 2001. Value Health 5:522–531CrossRef
20.
21.
22.
Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, O’Neill R, Kennedy DL (2007) Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 10(Suppl 2):S125–S137CrossRef
23.
US Department of Health and Human Services, US Food and Drug Administration (2009) Guidance for industry: patient-reported outcome measures. use in medical product development to support labeling claims. US Food and Drug Administration, Washington, DC
24.
European Medicines Agency, Committee for Medicinal Products for Human Use (CMHP) (2005) Reflection paper on the regulatory guidance for the use of Health-Related Quality of Life (HRQL) measures in the evaluation of medicinal products. European Medicines Agency, London
25.
Flokstra-de Blok BMJ, Dubois AEJ, Vlieg-Boerstra BJ, Oude Elberink JNG, Raat H, DunnGalvin A, Hourihane JOB, Duiverman EJ (2010) Health-related quality of life of food allergic patients: comparison with the general population and other diseases. Allergy 65:238–244CrossRef
26.
Goossens NJ, Flokstra-de Blok BM, van der Meulen GN, Arnlind MH, Asero R, Barreales L et al (2014) Health-related quality of life in food-allergic adults from eight European countries. Ann Allergy Asthma Immunol 113(63–8):e1
27.
Dunn Galvin A et al (2016) An examination of the Food Allergy Quality of Life Questionnaire performance in a countrywide American sample of children: cross-cultural differences in age and impact in the United States and Europe. J Allergy Clin Immunol Pract 5(2):363–368.e2CrossRef
28.
Flokstra-de Blok BM, Dubois AE (2012) Quality of life measures for food allergy. Clin Exp Allergy 42:1014–1020CrossRef
29.
Flokstra-de Blok BM, Dubois AE (2009) Quality of life in food allergy: valid scales for children and adults. Curr Opin Allergy Clin Immunol 9:214–221CrossRef
30.
Flokstra-de Blok BM, Dunn Galvin A, Vlieg-Boerstra BJ, Oude Elberink JN, Duiverman EJ, Hourihane JO et al (2009) Development and validation of a self-administered Food Allergy Quality of Life Questionnaire for children. Clin Exp Allergy 39:127–137CrossRef
31.
Flokstra-de Blok BM, Dunn Galvin A, Vlieg-Boerstra BJ, Oude Elberink JN, Duiverman EJ, Hourihane JO et al (2008) Development and validation of the self-administered Food Allergy Quality of Life Questionnaire for adolescents. J Allergy Clin Immunol 122:139–144CrossRef
32.
Flokstra-de Blok BM, van der Meulen GN, Dunn Galvin A, Vlieg-Boerstra BJ, Oude Elberink JN, Duiverman EJ et al (2009) Development and validation of the Food Allergy Quality of Life Questionnaire - adult form. Allergy 64:1209–1217CrossRef
33.
Dunn Galvin A, Flokstra de Blok BM, Burks AW, Dubois AE, Hourihane JO (2008) Food allergy QoL questionnaire for children aged 0-12 years: content, construct, and cross-cultural validity. Clin Exp Allergy 38:977–986CrossRef
34.
Dunn Galvin A, Cullinane C, Daly D, Flokstra-de Blok B, Dubois A, Hourihane J (2010) Longitudinal validity and responsiveness of the Food Allergy Quality of Life Questionnaire–Parent Form in children 0–12 years following positive and negative food challenges. Clin Exp Allergy 40:476–485CrossRef
35.
van der Velde JL, Flokstra-de Blok BM, Vlieg-Boerstra BJ, Oude Elberink JN, Schouten JP, Dunngalvin A et al (2009) Testretest reliability of the Food Allergy Quality of Life Questionnaires (FAQLQ) for children, adolescents and adults. Qual Life Res 18:245–251CrossRef
36.
Ferrans CA, Zerwic JJ, Wilbur JE, Larson JL (2005) Conceptual model of health-related quality of life. J Nurs Scholarsh 37:336–342CrossRef
37.
Flokstra-de Blok BMJ (2014) Food Allergy Quality of Life Questionnaires (FAQLQ) Encyclopedia of quality of life and well-being research. Springer, p 2319–322
38.
Buchanan AD, Green TD, Jones SM, Scurlock AM, Christie L, Althage KA et al (2007) Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol 119:199–205CrossRef
39.
Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W et al (2011) Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 127:640–646CrossRefPubMedCentral
40.
Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S, Steele P, Driggers S, Burks AW, Wood RA (2012) The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol 129:448–455CrossRef
41.
Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, Palmer C, Deighton J, Ewan P, Clark A (2014) Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 383:1297–1304CrossRefPubMedCentral
42.
43.
Dupont C, Kalach N, Soulaines P, Legoue-Morillon S, Piloquet H, Benhamou PH (2010) Cow’s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 125:1165–1167CrossRef
44.
Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT (2011) Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol 127:1622–1624CrossRefPubMedCentral
45.
Nurmatov U, Dhami S, Arasi S, Pajno GB, Fernandez-Rivas M, Muraro A, Roberts G, Akdis C, Alvaro-Lozano M, Beyer K, Bindslev-Jensen C, Burks W, du Toit G, Ebisawa M, Eigenmann P, Knol E, Makela M, Nadeau KC, O’Mahony L, Papadopoulos N, Poulsen LK, Sackesen C, Sampson H, Santos AF, van Ree R, Timmermans F, Sheikh A (2017) Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy 72:1133–1147CrossRef
46.
Chin SJ, Vickery BP, Kulis MD, Kim EH, Varshney P, Steele P, Kamilaris J, Hiegel AM, Carlisle SK, Smith PB, Scurlock AM, Jones SM, Burks AW (2013) Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison. J Allergy Clin Immunol 132:476–478CrossRefPubMedCentral
47.
Agbotounoi W, Martin L, Dupont D, Pascal I, Vauleon C, Benhamou PH (2012) Epicutaneous immunotherapy (EPIT) is safe for the treatment of peanut allergy in allergic patients [abstract]. J Allergy Clin Immunol 131(2 Suppl):AB91
48.
Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, Kamilaris J, Burks AW (2009) Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol 124:286–291CrossRefPubMedCentral
49.
Muraro A, Dubois AE, Dunn Galvin A et al (2014) EAACI Food Allergy and Anaphylaxis Guidelines. Food allergy health-related quality of life measures. Allergy 69:845–853CrossRef
50.
Avery NJ, King RM, Knight S, Hourihane JO (2003) Assessment of quality of life in children with peanut allergy. Pediatr Allergy Immunol 14:378–382CrossRef
51.
Polloni L, Baldi I, Lazzarotto F, Bonaguro R, Toniolo A, Gregori D, Muraro A (2015) Multidimensional analysis of food-allergic children and adolescents’ self-concept: a comparison with a healthy matched sample. J Health Psychol 20(6):850–857CrossRef
52.
Dunn Galvin A, Gaffney A, Hourihane JO’B (2009) Developmental pathways in food allergy: a new theoretical model. Allergy 64:560–568CrossRef
53.
Dunn Galvin A, Polloni L, Le Bovidge J, Muraro A, Greenhawt M, Taylor S, Burks W, Allen K, Sheikh A, Hourihane J, Tang M Development of the Food Allergy Coping and Experience Model (FACE): secondary analysis of data on IgE-mediated food allergy in children, young people and their parents from five countries. (JACI-P, accepted)
54.
DunnGalvin et al (2009) Profiling families enrolled in immunotherapy studies. Pediatrics 142(3):e503–e509CrossRef
55.
56.
Klinnert MD, Silveira L, Harris R, Moore W, Atkins D, Fleischer DM, Menard-Katcher C, Aceves S, Spergel JM, Franciosi JP, Furuta GT (2014) Health related quality of life over time in children with eosinophilic esophagitis (EoE) and their families. J Pediatr Gastroenterol Nutr 59(3):308–316CrossRefPubMedCentral
57.
Cortina S, McGraw K, de Alarcon A et al (2010) Psychological functioning of children and adolescents with eosinophil-associated gastrointestinal disorders. Child Health Care 39:266–278CrossRefPubMedCentral
58.
Klinnert MD, Moore W, Miller J et al (2011) Impact of eosinophilic esophagitis on quality of life for youth and their families. J Allergy Clin Immunol 127(S):AB110
59.
Mukkada V, Haas A, Creskoff Maune N et al (2010) Feeding dysfunction in children with eosinophilic gastrointestinal diseases. Pediatrics 126:e1–e7CrossRef
60.
Ingerski L, Modi A, Hood K et al (2010) Health-related quality of life across pediatric chronic conditions. J Pediatr 156:639–644CrossRefPubMedCentral
61.
Harris RF, Menard-Katcher C, Atkins D, Furuta GT, Klinnert MD (2013) Psychosocial dysfunction in children and adolescents with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 57:500–505CrossRef
62.
63.
Dunn Galvin A PAAM 2017 Symposium. Maternal Anxiety & Food avoidance
64.
65.
McHenry, Watson (2014) Impact of primary food allergies on the introduction of other foods amongst Canadian children and their siblings. Allergy, Asthma Clin Immunol 10(1):26CrossRef
66.
Barnett J, Muncer K, Leftwich J, Shepherd R, Raats MM, Gowland MH, Grimshaw K, Lucas JS (2011) Using ‘may contain’ labelling to inform food choice: a qualitative study of nut allergic consumers. BMC Public Health 11:734CrossRefPubMedCentral
67.
Beyer K, Eckermann O, Hompes S, Grabenhenrich L, Worm M (2012) Anaphylaxis in an emergency setting - elicitors, therapy and incidence of severe allergic reactions. Allergy 67:1451–1456CrossRef
68.
Kelleher MM, Hourihane JO’B, Dunngalvin A, Cullinane C, Fitzsimons J, Sheikh A (2012) A 24-h helpline for access to expert management advice for food allergy-related anaphylaxis in children: protocol for a pragmatic randomised controlled trial. BMJ 131(2 Suppl):AB219
69.
Calsbeek H, Rijken M, Dekker J, van Berge Henegouwen GP (2006) Disease characteristics as determinants of the labour market position of adolescents and young adults with chronic digestive disorders. Eur J Gastroenterol Hepatol 18:203–209CrossRef
70.
71.
Dunn Galvin A (2017) The experience of eating out on the Island of Ireland in 2013 prior to and following introduction of the ‘Food Information for Consumers Regulation’. Safe Food Report
72.
Dunn Galvin A, Roberts G et al Understanding how consumers with allergies make decisions based on precautionary labelling. Submitted
73.
Compas BE, Jaser SS, Dunn MJ, Rodriguez EM (2012) Coping with chronic illness in childhood and adolescence. Annu Rev Clin Psychol 8:455–480CrossRef
74.
Greenhawt M, Dunn Galvin A Preliminary psychometric analyses and clinical performance of a caregiver self-efficacy scale for food allergy self-management. Ann Allergy Asthma Immunol (in press)
75.
Baxter P, Jack S (2008) Qualitative case study methodology: study design and implementation for novice researchers. Qual Rep 13(4):544–559
76.
DunnGalvin et al Preliminary Development of the Food Allergy Coping and Emotions (FACE) questionnaires for children, adolescents and young people: qualitative analysis of data on IgE-mediated food allergy from five countries. (JAIP, accepted)
77.
78.
Bandura A (1977) Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev 84:191–215CrossRef
79.
Tamagawa R, Garland S, Vaska M, Carlson LE (2012) Who benefits from psychosocial interventions in oncology? A systematic review of psychological moderators of treatment outcome. J Behav Med 35(6):658–673CrossRef
80.
81.
Sifneos PE (1973) The prevalence of “alexithymic” characteristics in psychosomatic patients. Psychother Psychosom 22:255–262CrossRef
82.
Baiardini I, Abbà S, Ballauri M, Vuillermoz G, Braido F (2011) Alexithymia and chronic diseases: the state of the art. G Ital Med Lav Ergon 33(1 Suppl A):A47–A52PubMed
83.
Polloni L, Ferruzza E, Ronconi L, Lazzarotto F, Bonaguro R, Toniolo A, Celegato N, Muraro A (2015) Mental health and behavior of food-allergic adolescents compared to a healthy matched sample. Ann Allergy Asthma Immunol 115(2):158–160CrossRef
84.
Lumley MA, Stettner L, Wehmer F (1996) How are alexithymia and physical illness linked? A review and critique of pathways. J Psychosom Res 41:505–518CrossRef
85.
Kano M, Fukudo S (2013) The alexithymic brain: the neural pathways linking alexithymia to physical disorders. Biopsychosoc Med 7:1CrossRefPubMedCentral
86.
Bruni R, Serino FM, Galluzzo S, Coppolino G, Cacciapaglia F, Vadacca M et al (2006) Alexithymia and neuroendocrine-immune response in patients with autoimmune diseases: preliminary results on relationship between alexithymic construct and TNF-α levels. Ann N Y Acad Sci 1069:208–211CrossRef
87.
Guilbaud O, Curt F, Perrin C, Chaouat G, Berthoz S, Dugré-Le Bigre C et al (2009) Decreased immune response in alexithymic women: a cross-sectional study. Biomed Pharmacother 63:297–304CrossRef
88.
Guilbaud O, Corcos M, Hjalmarsson L, Loas G, Jeammet P (2003) Is there a psychoneuroimmunological pathway between alexithymia and immunity? Immune and physiological correlates of alexithymia. Biomed Pharmacother 57:292–295CrossRef
89.
Knibb RC, Horton SL (2008) Can illness perceptions and coping predict psychological distress amongst allergy sufferers? Br J Health Psychol 13(Pt 1):103–119CrossRef
90.
Polloni L, Dunn Galvin A, Ferruzza E, Bonaguro R, Lazzarotto F, Toniolo A, Celegato N, Muraro A (2017) Coping strategies, alexithymia and anxiety in young patients with food allergy. Allergy 72:1054–1060CrossRef
91.
Wasserman RL, Sugerman R, Mireku-Akomeah L, Gallucci AR, Pence DM, Long NA (2011) Peanut oral immunotherapy (OIT) of food allergy (FA) carries a significant risk of eosinophilic esophagitis (EoE). JACI 127(Issue 2, Supplement):AB28
92.
Greenhawt M Personal communication. (I have emailed for permission)
93.
Otani M, Bégin P, Kearney C, Dominguez T, Mehrotra A, Bacal LR, Wilson SK (2013) Multi-allergen oral immunotherapy improves quality of life in subjects with food allergies. JACI 131(Issue 2, Supplement):AB58
94.
Otani M, Bégin P, Kearney C, Dominguez T, Mehrotra A, Bacal LR, Wilson SK (2014) Multiple-allergen oral immunotherapy improves quality of life in caregivers of food- allergic pediatric subjects. JACI 10:25
95.
Factor JM, Mendelson L, Lee J, Nouman G, Lester MR (2012) Effect of oral immunotherapy to peanut on food-specific quality of life. Ann Allergy Asthma Immunol 109(5):348–352.e2 08.015CrossRef
96.
Tang MLK, Hsiao KC (2016) An update on oral immunotherapy for the treatment of food allergy. Paediatr Child Health 26:304–309CrossRef
97.
Kuang-Chih H, Ponsonby AL, Axelrad C, Tang M (2017) Long term effects of a probiotic and peanut oral immunotherapy (PPOIT) treatment on peanut allergic children. J Allergy Clin Immunol 139(2 Suppl):AB136
98.
99.
Gupta RS, Springston EE, Kim JS, Smith B, Pongracic JA, Wang X, Holl J (2010) Food allergy knowledge, attitudes, and beliefs of primary care physicians. Pediatrics 125:126–132CrossRef
100.
Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33:337–343CrossRef
101.
Macran S, Weatherly H, Kind P (2003) Measuring population health: a comparison of three generic health status measures. Med Care 41:218–231.11PubMed
102.
Martin LR, Williams SL, Haskard KB, DiMatteo MR (2005) The challenge of patient adherence. Ther Clin Risk Manag 1(3):189–199PubMedPubMedCentral
103.
McKenna SP, Ratcliffe J, Meads DM, Brazier JE (2008) Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes 6:65CrossRefPubMedCentral
104.
Doward LC, McKenna SP, Meads DM, Ratcliffe J, Whalley D, Langley PC (2002) Investigation into the feasibility of deriving relative and absolute utility from the Recurrent Genital Herpes Quality of Life Questionnaire (RGHQoL). Value Health 5:573–574CrossRef
Metadaten
Titel
Psychosocial Mediators of Change and Patient Selection Factors in Oral Immunotherapy Trials
verfasst von
Audrey Dunn Galvin
J.O’B. Hourihane
Publikationsdatum
03.10.2018
Verlag
Springer US
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 2/2018
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-018-8700-5

Weitere Artikel der Ausgabe 2/2018

Clinical Reviews in Allergy & Immunology 2/2018 Zur Ausgabe

ReviewPaper

The Impact of Baked Egg and Baked Milk Diets on IgE- and Non-IgE-Mediated Allergy

ReviewPaper

Enhancing the Safety and Efficacy of Food Allergy Immunotherapy: a Review of Adjunctive Therapies

ReviewPaper

The Current State of Epicutaneous Immunotherapy for Food Allergy: a Comprehensive Review

Correction

Correction to: Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies

ReviewPaper

Oral and Sublingual Immunotherapy for Treatment of IgE-Mediated Food Allergy

ReviewPaper

Mechanisms of Oral Tolerance

Neu im Fachgebiet HNO

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Nur selten Nachblutungen nach Abszesstonsillektomie

03.05.2024 Tonsillektomie Nachrichten

In einer Metaanalyse von 18 Studien war die Rate von Nachblutungen nach einer Abszesstonsillektomie mit weniger als 7% recht niedrig. Nur rund 2% der Behandelten mussten nachoperiert werden. Die Therapie scheint damit recht sicher zu sein.

Rezidivierender Peritonsillarabszess nach Oralsex

02.05.2024 Peritonsillarabszess Kasuistik

Die erotischen Dimensionen von Peritonsillarabszessen scheinen eng begrenzt zu sein. Das heißt aber nicht, solche Abszesse und Erotik hätten nichts miteinander gemein, wie ein Fallbericht verdeutlicht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise